Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adlai Nortye Enters Into Global Licensing Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Adlai Nortye Enters Into Global Licensing Agreement

With Eisai for EP4 Antagonist

By: Betsy Louda

, Contract Pharma

Adlai Nortye Biopharma has entered into a Global Licensing Agreement with Eisai. Under the terms of the Agreement, Adlai Nortye will have exclusive worldwide research, development, manufacture and commercialization rights to E7046, excluding Japan and part of Asia other than Mainland China (“Territory”).

 

E7046 is an investigational, oral EP4 antagonist with high activity and high selectivity. Based on preliminary results, it is well tolerated in patients with solid tumors. Phase 1b combination studies with radiotherapy and chemoradiotherapy are in progress.

 

“With its proposed mechanism of action and impressive preclinical results, we believe that E7046 will become a key component in furthering development of our oncology pipeline,” said Dr. Ruirong Yuan, chief medical officer and president of Adlai Nortye. “In preclinical studies, E7046 combined with radiotherapy, chemoradiotherapy and with immune checkpoint inhibitors demonstrated antitumor activity in different malignancies, including colon rectal cancer, lung cancer and some PD-1 resistant tumor models. We believe that E7046 has great potential for future clinical application in cancer treatment.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics